HealthSTAT News
STAT+: GSK sees its return to cancer starting to pay off
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
Join the argument
House rules →Comments load as you scroll.